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Background. Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent inva-
sion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most 
reported in children 5–15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent 
expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children 
in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that 
was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, 
Malawi.
Methods. In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 chil-
dren 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal 
serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity 
sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018. 
Results. All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood 
culture–confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn 
before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed 
actively for adverse events and serious adverse events.
Conclusions. The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or sig-
nificant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage 
and associated health inequity in the world’s poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact 
and programmatic use of TCVs within an endemic setting.
Clinical Trials Registration. NCT03299426.
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Typhoid fever is an acute, systemic infection caused by the 
ingestion of the human restricted pathogen Salmonella enterica 
serovar Typhi (S. Typhi) [1]. Typhoid fever affects an estimated 
12–27 million people globally each year, with 129 000–223 000 
related deaths [2–5]. In endemic areas, the highest incidence 
of typhoid fever has been found in school-aged children 
(5–15 years) [6, 7], but typhoid is increasingly being recognized 
in children under 5 years of age [4, 5]. In countries with inad-
equate sanitation and water contamination, infections may be 
acquired from water and food contaminated with human waste 
[8]. In addition, typhoid may be transmitted via a food vehicle 
if handled by an individual who is a chronic carrier of S. Typhi 
[9].
The epidemiology of typhoid fever in Africa has been less well 
studied than in Asia. The recent Typhoid Fever Surveillance in 
Africa Program measured the incidence of invasive Salmonella 
bloodstream infections across 13 sites in 10 countries, with inci-
dence estimates ranging from 0 to 383 per 100 000 in different 
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sites. The incidence was highest in the 2–14-year age group and, 
importantly, 47% of S. Typhi isolates were multidrug resistant 
[10]. Updated incidence estimates following this study decreased 
in east Africa, to 348 per 100 000 people, but increased in west 
Africa, to 422 per 100  000 people [11]. Outbreaks of multi-
drug-resistant (MDR) typhoid fever have occurred through-
out sub-Saharan Africa in recent years—including in Malawi, 
Uganda, Zimbabwe, Zambia, and the Democratic Republic 
of Congo—caused by strains that have been demonstrated to 
have originated in Asia. The rapid international spread of MDR 
typhoid is of great concern [12–16].
Starting in 1998, the Malawi Liverpool Wellcome Trust 
Clinical Research Programme has systematically collected 
blood and cerebrospinal fluid for culture from febrile patients 
at the Queen Elizabeth Central Hospital (QECH) in Blantyre, 
Malawi [17]. Between 1998 and 2010, there were approxi-
mately 14 cases of S. Typhi per year, with 6.8% demonstrating 
multidrug resistance. A rapid increase in cases began in 2011, 
peaking in 2014 with 782 cases and providing a minimum in-
cidence estimate for Blantyre of 184/100  000 person-years of 
observation. These infections have resulted in a high mortality 
rate (2.5%), despite use of fluoroquinolone antibiotics [18, 19]. 
This increase is almost entirely due to the emergence and spread 
of the MDR H58 haplotype of S. Typhi. Mathematical modeling 
suggests the incidence will decline, then settle to a stable, en-
demic level [20, 21]. In Malawi, typhoid is isolated throughout 
the year, but does have a seasonal pattern, peaking at the end 
of the wet season and during the early dry season. Through the 
Strategic Typhoid Alliance Across Africa and Asia program, 
large, community-based studies are ongoing and provide esti-
mates of disease burdens in the populations that will live in the 
site for this vaccine trial [22].
A new, first-generation typhoid Vi conjugate vaccine (Typbar-
TCV) has been developed by Bharat Biotech International, 
Hyderabad, India. This vaccine consists of 25 μg of Vi polysac-
charide, conjugated to a nontoxic tetanus toxoid protein carrier. 
Vi-TCV elicits a stronger anti-Vi response than unconjugated 
Vi polysaccharide, and the elicited antibodies have higher avid-
ity than those detected after the unconjugated Vi vaccine [23]. 
The safety and immunogenicity of Vi-TCV has been studied in 
adults and children down to 6 months of age in India, and is 
highly immunogenic [24].
In the Oxford controlled human infection model, a single 
dose of Vi-TCV was well tolerated and demonstrated 54.6% pro-
tective efficacy in healthy adults when the primary endpoint of 
blood culture positivity or prolonged fever was reached. When 
a more comparative endpoint to real-world efficacy was used, of 
fever followed by bacteraemia, efficacy increased to 87%, which 
is comparable to previous field trials of other typhoid conjugate 
vaccines (TCVs) [25, 26].
In October 2017, the World Health Organization’s (WHO) 
Strategic Advisory Group of Experts (SAGE), in recognition of 
the high burden of typhoid and the increase in antimicrobial 
resistance in low- and middle-income countries, recommended 
the introduction of TCVs for children older than 6  months in 
typhoid-endemic countries [27]. Following the SAGE recom-
mendation, Gavi announced an 85 million dollar window for 
2019–2020 to support the introduction of TCVs in low-income 
countries [28]. In December 2017, the WHO approved the pre-
qualification of Typbar-TCV, facilitating its introduction in 
low-income countries [29]. While these global policy and financ-
ing decisions are necessary for vaccine introduction in low-in-
come countries, they are generally not sufficient for country-level 
uptake, particularly in Africa, where TCVs have never been 
tested. Malawi is a Gavi-eligible country, but has not submitted an 
application for support at the time of writing. The timeline from 
application to Gavi to Gavi acceptance and the country introduc-
tion of the vaccine is approximately 18 months. Trial results will, 
therefore, precede any other introduction, providing valuable 
efficacy data for the African continent.
In summary, the Typbar-TCV Vi conjugate vaccine is a 
promising candidate for the control of typhoid fever in Africa, 
because of its 1-dose schedule and its demonstrated immuno-
genicity and safety profile in children. To date, no studies of the 
field efficacy of any TCV have been conducted in Africa [30]. 
This protocol is designed to demonstrate the impact of Vi-TCV 




This study is a double-blind, individually randomized, con-
trolled, efficacy trial with 2 vaccine groups: Vi-TCV and a 
meningococcal serogroup A  conjugate vaccine (MCV-A). 
Participants (up to 28 000) will be randomized in a 1:1 ratio. 
Children 9 months through 12 years of age in the Blantyre area 
who meet the inclusion criteria will be eligible for enrollment. 
Immediate adverse events will be monitored for all participants. 
Serious adverse events (SAEs) in all participants will be moni-
tored through to the end of the trial.
For the evaluation of efficacy, passive surveillance of febrile 
illnesses with blood culture collection will be conducted for 
24–30  months for each individual, to identify typhoid fever 
cases among vaccinated subjects. Additional information, in-
cluding the signs and symptoms of the illness and treatment 
given, will be collected from any child who has a blood culture 
obtained. Any child with blood culture–confirmed typhoid 
fever will have follow-up visits every other week until the ill-
ness resolves. Vaccine efficacy (VE) will be evaluated when the 
prespecified number of cases is reached, after a minimum of 
2 years of follow-up on each participant.
The primary study hypothesis is that the Vi-TCV vaccine 
is efficacious in preventing typhoid fever, as confirmed by 
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VE  ≤  0). The primary endpoint is clinical typhoid fever, 
confirmed by blood culture, with cases identified by passive 
surveillance in hospital and clinics. The secondary study 
hypothesis is that the safety profile of the Vi-TCV vaccine is 
adequate (Table 1).
Immunogenicity and Reactogenicity Sub-study
A subset of 600 children (200 in each of 3 age groups: 
9–11 months, 1–5 years, and 6–12 years) will be included in an 
Immunogenicity and Reactogenicity Sub-study. More stringent 
exclusion criteria will apply for this subset. Serum specimens 
will be collected on Day 0 (before vaccination) and on post-vac-
cination Days 28 and 730 from all children included in the 
sub-study. For the children in the 9–11 month group, Vi-TCV 
or MCV-A will be administered with a measles-rubella–con-
taining vaccine, as per the Malawi Expanded Programme on 
Immunization (EPI) schedule. These 9- to 11-month-old child-
ren will, additionally, have antibodies to measles and rubella 
assessed on Days 0 and 28. All children in the sub-study will 
be assessed at Days 3 and 7 following vaccination for the 
solicitation of local and systemic adverse events. Solicited and 
non-solicited non-SAEs will be assessed at Days 28 and 180. 
Serious adverse effects will be reported throughout the trial.
Trial Experimental and Control Vaccines
Rationale for Study Vaccine
Vi-TCV (TypBar-TCV) is a single-dose vaccine licensed down 
to 6 months of age, making it feasible for incorporation into the 
routine EPI schedule. Vi-TCV is the only TCV to have been 
prequalified by the WHO [29].
Rationale for Control Vaccine
The MCV-A, MenAfriVac, is a single-dose vaccine licensed 
for use from 9  months of age; it is prequalified by WHO 
and provides protection against disease caused by group 
A Neisseria Meningitidis. While Malawi is outside the Africa 
meningitis belt, meningococcal A infection is a serious dis-
ease with high case-fatality rates and long-term sequelae 
among survivors, and so this vaccine is of some benefit to 
the children in this trial.
Table 1. Study Objectives and Endpoints
Primary 
objective
1.  To determine the efficacy of Vi-TCV in reducing rates of symptomatic, blood culture–confirmed Salmonella Typhi infection among 
children who receive Vi-TCV, compared to children who receive MCV-A.
Secondary 
objectives
1. To determine the safety profile of vaccination with Vi-TCV or MCV-A.
 2.  To determine the immunogenicity of Vi-TCV in a subset of participants, by age group, as measured by serum, anti-Vi, IgG antibod-
ies (percent seroconversion and geometric mean titer) at approximately 28 days following vaccination and at 2 years following 
vaccination.
 3. To determine the number of blood culture–confirmed cases of typhoid fever prevented during the study period, by comparing the 
incidence of blood culture–confirmed typhoid fever in participants receiving Vi-TCV to the incidence in participants receiving MCV-A.
Exploratory 
objectives
1. To determine the effect of Vi-TCV on the number and duration of hospitalizations due to blood culture–confirmed typhoid fever and the 
number of hospitalizations due to typhoid fever prevented by Vi-TCV.
 2. To determine the effect of Vi-TCV on the duration of hospitalization for febrile illness during the study period.
 3.  To determine the effect of Vi-TCV for preventing all-cause hospitalizations and the number of hospitalizations prevented during the 
study period.
 4.  To describe the clinical characteristics of blood culture–confirmed typhoid fever in study participants, including the percentage of 
participants with specific signs and symptoms.
 5. To determine the effect of Vi-TCV on outpatient visits for fever and the number of visits prevented during the study period.
 6. To determine the effect of Vi-TCV on the number of outpatient and hospitalized cases of clinically diagnosed typhoid fever
 7.  To determine the effect of Vi-TCV on hospitalizations for febrile illness and the number of hospitalizations prevented during the study 
period.
 8.  To determine the effect of Vi-TCV on antibiotic usage and the number of antibiotic courses and days of antibiotic use prevented during 
the study period.
 9. To determine the effect of Vi-TCV on all-cause mortality and the number of deaths prevented during the study period.
 10.  To compare the number of episodes of illness for which blood cultures are collected during the study period between the Vi-TCV and 
MCV-A groups.
 11. To compare the incidence of hospitalizations for meningitis between the Vi-TCV and MCV-A groups.
 12. To evaluate the rate and recurrence of ileal perforations secondary to typhoid fever.
 13.  To determine the effect of Vi-TCV on the incidence of complications of typhoid fever (eg, perforations, acute abdominal procedures, 
death) and the number of complications prevented during the study period.
 14.  To determine the persistence of serum anti-Vi IgG antibodies in a subset of participants, by age group, at approximately 2 years 
following vaccination.
 15. To evaluate the efficacy and above outcomes by age groups.
 16.  To compare the anti-measles IgG percent seroprotection and geometric mean concentrations among 9–11-month-old children receiv-
ing Vi-TCV and measles-rubella vaccine and children receiving MCV-A and measles-rubella vaccine.
 17.  To evaluate the relationship between serum anti-Vi IgG at 28 days post-vaccination and the development of symptomatic, blood 
culture–confirmed Salmonella Typhi infection among children in the immunogenicity subset.
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Study Population
Children aged 9  months through 12  years who reside within 
the townships of Ndirande and Zingwangwa, Blantyre, will be 
considered for enrollment.
Inclusion/Exclusion Criteria
The study will enroll healthy children between 9 months and 
12  years/364  days of age at the time of study vaccination. 
Inclusion and exclusion criteria are broad for the main effi-
cacy study, to simulate the general population of the Blantyre 
area (Table 2). The safety and immunogenicity sub-study will 
exclude children with known acute or chronic illnesses or 
severe malnutrition, which could interfere with the assessment 
of the safety and immunogenicity of the vaccine (Table 3).
Recruitment and Vaccination
Recruitment will primarily occur in schools, with commun-
ity and health-care centers also used. In schools, children will 
be given study information to take home and parents will be 
invited to attend a school-based vaccine clinic. The study 
will be explained, the requirements discussed, and questions 
answered by study staff. The parents/guardians of the children 
will then have the opportunity to provide informed consent. 
Assent will be obtained for all children 8 years of age and older. 
After informed consent and assent are obtained, each poten-
tial participant will be screened for eligibility according to the 
inclusion/exclusion criteria. The medical history, concomitant 
medications, and measles-rubella vaccination history, along 
with temperature, will be recorded. Once this is complete, and 
all eligibility criteria are verified, participants will be adminis-
tered either Vi-TCV or MCV-A.
All study participants will be asked to remain in the study 
area for at least 30 minutes immediately following vaccination, 
in case there is a serious reaction. Any immediate reactions will 
be assessed and recorded.
Randomization
Enrolled participants will be randomly assigned in a 1:1 ratio to 
either the Vi-TCV group or the MCV-A group, using block ran-
domization, with varying block sizes from 6–12. The random 
allocation sequence will be generated by the blockrand package 
(version 1.3) in R (version 3.4.1) [31, 32].
Study participants, their family members, and the study staff 
involved in recruitment and eligibility will be unaware of the 
assigned vaccine group. The staff who prepare and administer 
the vaccines will be aware of the assigned vaccine group, but 
will not be involved in passive surveillance or any other subse-
quent study procedures.
Table 2. Inclusion and Exclusion Criteria
Inclusion 
criteria
A healthy male or female child between the ages of 9 months and 12 years/364 days at the time of study vaccination.
 A child whose parent or guardian resides primarily within the Ndirande or Zingwangwa study areas at the time of study vaccinations, and 
who intends to be present in the area for the duration of the trial.
 A child whose parent or guardian has voluntarily given informed consent.
Exclusion 
criteria
A history of documented hypersensitivity to any component of the vaccine.
 Prior receipt of any typhoid vaccine in the past 3 years.
 A history of a severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis.
 Any condition determined by the investigator to be likely to interfere with evaluation of the vaccine, to be a significant potential health risk 




The following will be considered temporary contraindications to enrollment and vaccination. If these apply, the participant will be tempo-
rarily excluded for vaccination until 48 hours has passed. A reassessment will be needed to ensure these temporary exclusion criteria no 
longer exist.
 • Reported fever within 24 hours prior to vaccination.
• Use of anti-pyretics within 4 hours prior to vaccination.
• Receipt of measles-rubella vaccine in the 1 month prior to enrollment, as determined by parental history or vaccination card.
Table 3. Additional Exclusion Criteria for Immunogenicity and Reactogenicity Sub-study
•  A known history of diabetes, tuberculosis, cancer, chronic kidney disease, heart disease, liver disease, a progressive neurological 
disorder, poorly controlled seizures, or a terminal illness.
• Severe malnutrition, as determined by mid-upper arm circumference < 12.5 cm for children younger than 5 years.
•  The receipt of any other investigational intervention in the prior 6 months or the anticipated receipt during the course of the 
study.
• The receipt of blood products in the last 6 months.
• A known human immunodeficiency virus infection or exposure, or any other immunosuppressive condition.
• The receipt of systemic immunosuppressants or systemic corticosteroids.











ollege London) user on 13 M
arch 2019
S54 • CID 2019:68 (Suppl 2) • Meiring et al
An unblinded version of the allocation sequence will 
be maintained by an unblinded site statistician for use in 
unblinding according to protocol or for the assignment of 
replacement vials, should the original assigned vaccine be dam-
aged or prepared incorrectly. Both the site statistician and the 
site data manager programming the study tablets have access to 
the unblinded randomization table, but will not be part of the 
clinical team and will not share the list with any team members 
responsible for study conduct.
This is a single-dose vaccine intervention and, therefore, we 
anticipate that any circumstances warranting unblinding will 
be rare. However, circumstances may arise where unblinding 
is needed prior to the end of the study. In such circumstances, 
the Independent Safety Monitor, who will be a physician in 
Malawi who is not a study investigator, will assess the child. 
The details will be reported to the Sponsor and the Data Safety 
Monitoring Board (DSMB). If necessary, the DSMB will recom-
mend unblinding to the study sponsor. Any event of unblinding 
will be fully documented in the case report form.
Follow-up
Passive Surveillance for Efficacy Study
Passive surveillance will be conducted throughout the study 
to identify outcomes among vaccinated subjects. All children 
attending primary or secondary health facilities in the study area 
will be screened, and those enrolled in the trial will have data 
pertinent to all endpoints collected. Those who meet the proto-
col-defined specimen collection criteria will have a blood culture 
collected (Figure 1). If a blood culture is positive for S. Typhi, the 
participant will be followed up by study staff to ensure appropri-
ate treatment. Further information on blood-culture–confirmed 
typhoid illness will be obtained, and the participant will be fol-
lowed every 2 weeks until asymptomatic.
To determine the effect of vaccination on the number of out-
patient visits, number of hospitalizations, and antibiotic usage, 
passive surveillance will be conducted throughout the study for 
study participants who visit outpatient facilities or tertiary-level 
facilities or who are admitted to QECH but do not meet the 
protocol-defined specimen collection criteria. Information 
will be recorded, including the purpose of the visit, duration of 
symptoms, primary diagnosis, prescribed treatment, and dates 
of admission and discharge/loss to follow-up/death. SAEs, 
whether or not associated with study participation, will be 
recorded for the duration of the study.
Active Follow-up for Sub-study
Children in the immunogenicity and reactogenicity sub-study 
will have home or clinic visits on Days 3, 7, and 180 following 
vaccination, at which solicited and unsolicited adverse events 
will be recorded. On Days 28 and 730 following vaccination, 
participants will attend the clinic for a 5 mL blood draw to mea-
sure typhoid-Vi antibody responses (all age groups) and measles 
and rubella antibody responses (9- to 11-month-old age group 
only. Children in the sub-study who are less than 5 years of age 
will have their height, weight, and mid–upper arm circumfer-
ences measured at baseline and at 2 years after vaccination.
Statistics
Sample Size and Power Calculations
The number of blood-culture confirmed typhoid cases in the 
Vi-TCV and MCV-A groups are x1 and x2, respectively. The per-
son-years of follow-up in the Vi-TCV and MCV-A groups are f1 






× 100% = 1− x1
x2
h
where h  =  f2/f1 is the ratio of the follow-up person-years 
between the 2 vaccine groups, which is expected to be 1 due to 
randomization.
Now, letting P = x1/(x1+ x2), the proportion of blood culture–
confirmed typhoid cases in the Vi-TCV group, we have





1− VE + h
Then, we can test the null hypothesis that the vaccine has 
no protective efficacy (H0: VE  ≤  0) by testing the equivalent 
hypothesis that P ≥ 1(1 + h) = 0.5, since we expect h to be 1.
If we assume that the VE is 80%, then the hypotheses H0: 
VE ≤ 0 vs Ha: VE = 0.8 can be rewritten as H0: P ≥  .5 vs Ha: 
P  =  .16667. A  sample size of 23 blood culture–confirmed 
Figure 1. Passive surveillance enrollment flow. Abbreviations: SAE, serious 
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typhoid cases is needed to achieve 90% power to detect the dif-
ference of 0.33 (= 0.5 − 0.16667) using a 2-sided exact test with 
a significance level of 0.025 (PASS 15). If we assume the attack 
rate is 0.0009 per year in the control group and each subject will 
be followed for 2 years, the total number of subjects that needs 
to be enrolled to result in the 23 required typhoid cases is 25 
058, after accounting for a dropout rate of 15% (Table 4). With 
28 000 children enrolled, the required number of cases is likely 
to be achieved, with an average of 24 months of follow-up per 
participant. Lower efficacy, fewer children enrolled, or a lower 
than assumed attack rate will require longer follow-ups to reach 
the minimum number of cases (see Tables 4 and 5 for sample 
size calculations for other parameter settings).
Statistical Analyses
In the primary analysis, subjects will be analyzed according 
to the vaccine received, and those subjects who are not vacci-
nated or who are provided no follow-up after vaccination will 
be excluded from the analysis. The estimated incidence rate of 
blood culture–confirmed typhoid will be calculated as the num-
ber of blood culture–confirmed typhoid cases, divided by the 
total number of person-years of follow-up. The incidence rates 
and corresponding 95% confidence intervals will be calculated 
for each vaccine group. The incidence rate ratio (IRR) will be 
calculated as the ratio of the incidence rate in the Vi-TCV group 
to that in the MCV-A group, and the VE will be calculated as 
(1-IRR) × 100%. Poisson regression, with an offset for the 
length of follow-up, will be used to compute the IRR, VE, and 
corresponding 95% confidence intervals, while adjusting for 
potential confounding variables (such as age and sex) as needed. 
A sensitivity analysis will be conducted, based on a per-protocol 
population that includes all vaccinated subjects and a follow-up 
time beginning 14 days after vaccination. Typhoid cases occur-
ring before 14 days after vaccination will not be included in the 
sensitivity analysis of the per-protocol population. All analyses 
will be performed using Stata/SE (version 15).
Data Safety and Monitoring
An independent DSMB, including physicians and a statistician, will 
be established. This committee will meet before the study starts and 
will hold regular meetings for the duration of the trial. If a signifi-
cant safety concern arises during the study, the DSMB Chair may 
convene a meeting to review safety and any other aspects of the 
study. Significant safety events may include, but are not limited to:
 1. A death or life-threatening condition sustained by a partici-
pant, regardless of causality.
 2. An unexpected, serious safety issue that is newly identified 
during the program and could expose participants to unnec-
essary risks.
 3. Any other concern regarding participant safety, raised by any 
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Proposed study amendments that significantly alter the treat-
ment plan and/or deal with participant safety concerns will 
prompt an ad hoc meeting of the DSMB for review prior to the 
implementation of changes. This may require the suspension of 
enrollment pending a DSMB review.
Ethical Considerations
Human Subjects’ Protections
The study will be conducted in accordance with the principles 
of the Declaration of Helsinki and in accordance with the prin-
ciples of Good Clinical Practice (GCP).
Ethical/Institutional Review
This protocol, informed consent document, proposed advertis-
ing material, and participant information sheet will be submit-
ted to the Malawi National Health Science Research Committee, 
the University of Maryland Institutional Review Board, and the 
University of Liverpool Research Ethics Committee for written 
approval.
Informed Consent
Individual written informed consent will be sought from each 
child’s parent or guardian, according to GCP. The consent form 
will be signed or a thumbprint provided by the child’s parent or 
guardian before any procedures are conducted. If a parent or 
guardian is unable to read or sign the consent form, an impar-
tial witness will assist for the entire informed consent process, 
according to GCP. Written assent will be obtained from all chil-
dren aged 8 and over.
Data
Data Collection and Entry
Study data will be entered in real time into electronic tablets 
using the REDCap platform and uploaded daily by the in-coun-
try data team to a cloud-based, secure database. Individuals will 
be assigned personal identification numbers, readable from 
barcode or QR code stickers inserted in their individual health 
care records (which are held by the individual in Malawi) and 
used for consent and assent forms and for laboratory speci-
mens. Daily quality assurance checks and the reconciliation of 
recruitment and other data will occur between the data teams 
at the site and the Sponsor. The Sponsor will oversee the overall 
data management and quality assurance procedures.
Quality Management
The study will be conducted in accordance with the protocol-spe-
cific quality management plan, designed in conjunction with 
the University of Maryland Center for Vaccine Development 
Office of Regulatory Affairs and Quality Management. Staff will 
be trained in and adhere to the standard operating procedures 
(SOPs), contained in the study manual of procedures. Study 
data collection forms are designed to guide staff study conduct. 
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GCP, Human Subject Protection, and all SOPs prior to partici-
pant enrollment, with regular updates as stipulated.
Site monitoring will be conducted to ensure that human 
subject protection procedures and study procedures, including 
study vaccine administration and clinical data and biological 
specimen collection, are of high quality and that the study is 
conducted in accordance with the protocol. Any protocol viola-
tions will be recorded and reported accordingly to all IRBs and 
regulatory bodies, and a corrective action plan will be agreed 
and enacted.
After data have been entered in the study database, they will 
be checked systematically by data management staff, according 
to a prespecified data validation plan agreed by the site and the 
Sponsor. All listings of the database will be reviewed and dis-
cussed for data quality and will be assessed for consistency and 
medical plausibility. After the resolution of all issues, the sta-
tistical analysis plan will be finalized and the database will be 
locked after the resolution of any remaining queries. A robust 
audit trail will be kept of all subsequent changes to the data.
Plans for Dissemination of Results
When the clinical study report is completed, the investigators 
will share the summary results with the participating commu-
nities. It is anticipated that the results of this trial may have a 
significant bearing on policy decisions regarding the licen-
sure and use of TCV in Malawi and other countries in Africa. 
Additionally, summary results will be provided to the ethics 
committees and regulators.
DISCUSSION
This trial compares the effect of Vi-TCV to MCV-A on the blood 
culture–confirmed incidence of S. Typhi in Blantyre, Malawi, a 
typhoid-endemic setting. It is the first trial in Africa to test the 
effectiveness of TCVs and assess the safety and immunogenicity 
of this vaccine on the continent’s children.
The WHO has recommended the use of the vaccine from 
6  months of age, with health economic modelling showing 
catch-up campaigns to be the most impactful and cost-effective, 
dependent on local epidemiology [33]. However, countries have 
many demands on their health-care dollars, and additional data 
will assist countries in deciding when and how to best employ 
this vaccine [29, 33]. The study will provide important data on 
a number of health outcomes beyond efficacy, including anti-
microbial usage. The data for the 9-month-olds will inform 
introduction at that EPI visit, which could limit logistical and 
delivery costs and, in countries with high vaccine acceptability, 
like Malawi, could ensure high rates of uptake [34]. A  recent 
Cochrane review affirmed the importance of these field trials 
[35]. This study will also demonstrate the effectiveness of the 
vaccine after a single dose, which could be useful to limit and 
control the spread of disease in the context of typhoid epidem-
ics [12, 36].
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